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Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection SerialEM automated image acquisition software version 3.7; BLU-ICE X-ray data collection software at SSRL; Tecan Infinite M1000 plate reader 
software; Biacore T200 instrument software
Data analysis GraphPad Prism 8.4.3 was used for polyreactivity data analysis; XDS (Build 20200417), Xia2 v0.3.8, DIALS v2.2, and the CCP4 v7.0.6 suite of 
crystallographic programs (AIMLESS v0.7.4, PHASER v2.8.2), Sculptor v2.0, Phenix v1.18, Coot v0.8.9, cryoSPARC v2.15, CTFFIND4 v4.1.14, 
PyMOL v2.2, Chimera v1.13, ChimeraX-v1.0, and Molprobity v4.4 were used for structural analysis; Kinetic constants were calculated using 
Biacore T200 Evaluation Software v3.2; PDBePISA v1.48 for BSA calculations; 
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and 
reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
The atomic models generated from X-ray crystallographic studies of the C102-RBD complex, C102 Fab, C002 Fab, C110 Fab, C121 Fab, and C135 Fab have been 
deposited at the Protein Data Bank (PDB, http://www.rcsb.org/) under accession codes PDB 7K8M, 7K8N, 7K8O, 7K8P, 7K8Q, and 7K8R, respectively. The atomic 
models and cryo-EM maps generated from cryo-EM studies of the C002-S 2P (state 1), C002-S 2P (state 2), C104-S 2P, C110-S 2P, C119-S 2P, C121-S 2P (state 1), 
C121-S 2P (state 2), C135-S 2P and C144-S 6P complexes have been deposited at the PDB (http://www.rcsb.org/) and the Electron Microscopy Databank (EMDB, 
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http://www.emdataresource.org/) under the following accession codes: PDB 7K8S, 7K8T, 7K8U, 7K8V, 7K8W, 7K8X, 7K8Y, 7K8Z, and 7K90; EMD 22729, 22730, 
22731, 22372, 22733, 22734, 22735, 22736, and 22737. 
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Not applicable to this study, because no sample size calculation was performed to design the study.
Data exclusions No data were excluded.
Replication All experiments were replicated successfully, n values can be found in figure legends.
Randomization Not applicable to this study, as we do not report experiments that use randomized data.
Blinding Not applicable to this study, as we do not report any experiments that applied blinding.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
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Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Antibodies
Antibodies used HRP-conjugated anti-human IgG secondary antibody (SouthernBiotech, Catalog 2040-04; Goat Anti-Human IgG-HRP; Lot 
B3919.NEB80B) used at a 1:5000 dilution. All other antibodies reported were expressed in this study.
Validation Primary antibodies reported in this study were described previously in Robbiani et al. (doi:10.1038/s41586-020-2456-9). Target 
validation was done with multiple binding assays and structural studies using cryo-EM and X-ray crystallography. Control anti-HIV-1 
antibodies reported in this study have been previously described and validated in a polyreactivity assay (Schoofs, et al. doi:10.1016/
j.immuni.2019.04.014). Reactivity of the primary antibody listed above is based on the information on manufacturer's homepages.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) Expi293F (ThermoFisher cat. A14527)
Authentication Not authenticated after purchase.
Mycoplasma contamination The cell lines were not contaminated by mycoplasma as determined by using the Lonza Mycoplasma Detection Kit.
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified cell lines were used.
